Riliprubart demonstrated meaningful clinical benefit across all enrolled cohorts—SoC-Treated, SoC-refractory, and SoC-naïve—with improvement in functional measures (INCAT, I-RODS, MRC-SS, grip strength).
Encouraged by consistent Phase II results, two global Phase III trials in CIDP have now been launched, positioning riliprubart as a potential new class of targeted complement inhibitors in immune-mediated neuropathies.
At EAN 2025, new results from the ongoing Phase II trial (NCT04658472) of riliprubart, a first-in-class, subcutaneously self-administered IgG4 monoclonal antibody targeting activated-C1s in the classical complement pathway, underscored its poten...
